Navigation Links
Study Suggests Soy Protein May Reduce Prostate Cancer Risk
Date:10/4/2007

ST. LOUIS, Oct. 4 /PRNewswire/ -- A study published in the Oct. 1 Journal of Nutrition suggests consumption of soy protein may play a role in reducing the risk of prostate cancer, Solae notes, giving consumers another healthy reason to make soy part of their diet.

The study, "Soy protein isolate increases urinary estrogens and the ratio of 2:16 alpha-hydroxyestrone in men at high risk of prostate cancer," is believed to be the first study investigating the effects of soy protein consumption on estrogen metabolism and prostate cancer in men.

"The intent of the study was to evaluate the effects of consuming soy protein on elimination of estrogen metabolites in the urine of men at a high risk for prostate cancer," said Dr. Mindy Kurzer, lead author of the study and a professor in the Department of Food Science and Nutrition at the University of Minnesota. "After taking biopsies of prostate tissue, androgen receptors were reduced in the prostate, which is consistent with a reduced risk of prostate cancer. In addition, significantly fewer of the men who consumed soy protein progressed to cancer by the end of the six-month study. We are encouraged by the results, but more studies must be performed."

"The results of this study could be beneficial for men who are at risk of prostate cancer," said Dr. Kathryn Greaves, Group Lead, Clinical Nutrition at Solae. "If the results of this study are replicated in future studies, reducing the risk of prostate cancer may be another reason to include soy in your daily diet."

Soy has been documented to potentially improve heart health and aid in sports performance and weight management. For more information on Solae and its products, please visit http://www.solae.com.

About Solae

Solae is the world leader in developing innovative soy-based technology to the food, meat and nutritional products industries. Solae provides solutions that deliver a unique combination of functional, nutritional and economic benefits to our customers.

Headquartered in St. Louis, Missouri, USA, with annual revenue exceeding $1 billion, the company was formed through an alliance between Bunge Limited (NYSE: BG) and DuPont (NYSE: DD). For more information, visit http://www.solae.com.


'/>"/>
SOURCE Solae
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... Jersey , April 29, 2016 ... Suite for Life Sciences, Product Development Capabilities in ... Life Science Customer Base . ... provider, today announced the acquisition of Skura Corporation,s ... global leader in adaptive sales enablement technology for ...
(Date:4/28/2016)... , April 28, 2016  While Abbott,s ... complement the company,s valve repair and stent business, ... also places Abbott more firmly into patient monitoring.  ... the fastest growing device areas, with double-digit growth ... recent report,  Advanced Remote Patient Monitoring ...
(Date:4/28/2016)... April 28, 2016 Treato ... on healthcare, announced today that it has been named ... Cool Vendor in Life Sciences, 2016, Stephen ...  The report focuses on life-science- oriented analytics, algorithms and ... patients and doctors, confirm medication ingestion, and analyze unstructured ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... ... Carnival Vista – the line’s largest cruise ship ever. To help guests ... an infographic spotlighting the Carnival Vista ’s most exciting features and ...
(Date:5/2/2016)... ... ... It has just been announced Jack Uldrich, renowned futurist and ... of May. , Uldrich is the author of 11 books and a regular guest ... the Science Channel’s FutureScape and Discovery Channel’s Inside Out. , Known the world over ...
(Date:5/2/2016)... Dallas, Texas (PRWEB) , ... May 02, 2016 ... ... Volume 3, Issue 1 of Patient Experience Journal (PXJ), an international, open ... patient experience. With almost half the issue representing international (non-US) based authors, the ...
(Date:5/2/2016)... ... 02, 2016 , ... Beanfields, PBC, makers of Beanfields Bean ... students at University of Colorado in Boulder to create new advertising campaigns. , ... the School of Journalism, who selected Beanfields as the brand on which to ...
(Date:5/2/2016)... ... May 02, 2016 , ... Amica Life Insurance ... understand life insurance throughout various life stages. , The site launched on April ... calculator and content specific to the times when life insurance matters most. , ...
Breaking Medicine News(10 mins):